Condition
Photoageing
5 compounds were checked against photoageing. 1 earned a graded row; the rest are named below.
Last updated
Recorded under Skin ageing, alongside 2 other indications.
Compounds with a graded row
Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.
-
Palmitoyl Pentapeptide-4 (Matrixyl)
human RCT Direct outcome Not approved for this condition
- Who was studied
- Caucasian women aged 35-55 with photoaged facial skin, n=93, topical (3 ppm pal-KTTKS in a moisturiser), 12 weeks, split-face left-right randomised
The enrolled population was photoaged facial skin specifically: a 12-week double-blind, split-face, randomised comparison of a moisturiser with and without 3 ppm palmitoyl pentapeptide-4 measured wrinkles and fine lines in photodamaged skin by image analysis and expert grading, and reported improvement versus the placebo side. It is a single cosmetic-industry trial with no independent replication on file, and the peptide has no regulatory approval for any skin condition.
Source DOI 1 primary source read for this row
Recorded absences
3 compounds are listed here without a rung. Each row exists to mark a distinction a reader would otherwise draw wrongly, and each says what is missing rather than leaving the compound off the page.
-
Melanotan I
No rung — nothing on file to grade Not approved for this condition
Afamelanotide is approved for photoprotection in erythropoietic protoporphyria and has randomised trials in vitiligo and photodermatoses, but no trial has enrolled photoaged skin or measured a photoageing endpoint such as wrinkling, elastosis or dyschromia from cumulative sun exposure. The approved indication is prevention of phototoxic pain, not repair of photodamage.
-
Myristoyl Pentapeptide-17
No rung — nothing on file to grade Not approved for this condition
No study has enrolled photoaged skin or measured a photoageing endpoint for this compound.
-
Snap-8
No rung — nothing on file to grade Not approved for this condition
No study of acetyl octapeptide-3 has enrolled photoaged skin or measured a photoageing endpoint. The peptide's claims circulate in supplier material; no trial against photodamage exists in PubMed or Europe PMC.
Checked, and nothing recorded
1 compound was checked against photoageing and produced no gradeable row.
A compound is here because someone looked and the sources did not support a row — not because nobody looked. Under the rubric, uncertainty resolves to no row, and a row resting on a vendor page or a clinic blog is worse than no row at all.
What this page does not say
It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a row here is a record of a study rather than a reason to use anything. Every rung links to the rubric that assigned it.